Hormonal
Males with severe obesity experience significantly greater excess body weight loss and greater reduction in gamma-glutamyl transferase (a marker for NAFLD) compared to females following a 25-day very low-carbohydrate ketogenic diet (VLCKD).
If you are female, you may lose less weight and see less improvement in liver health markers than a male following the exact same very low-carb ketogenic diet protocol. This is likely due to differences in body fat distribution and hormones. Do not assume your results will match male benchmarks; focus on consistency and consult a professional to adjust expectations.
Males experienced a significantly larger excess body weight loss (EBWL) and a greater reduction in γ-glutamyl transferase (γGT) than females.
Why this rating
The study is a pilot study with a small sample size (n=70) and short duration (25 days), limiting generalizability.
Source
Very Low-Carbohydrate Ketogenic Diet for the Treatment of Severe Obesity and Associated Non-Alcoholic Fatty Liver Disease: The Role of Sex Differences
Marco D’Abbondanza et al. · Nutrients · 2020
DOI 10.3390/nu12092748
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →